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For the first time efficacy and safety of a new prostaglandin E 1 (I'GE1) regimen in the 
treatment of intermittent claudication were evaluated in a randomized, ouble-blind, plaee- 
bo-controlled multicenter clinical trial. The study involved 213 outpatients with a maximum 
walking distance of 50 to 200 m measured on the treadmill (3 km/hr,  12% grade). After a 
2-week run-in phase they received a 2-hour intravenous infusion of 60 Itg PGE 1 or placebo 5
days a week for 4 weeks. I t  was followed by a 4-week interval treatment with e same 
medication administered only twice a week. Patients were monitored for 3 months when they 
received no study medication. In the PGE1 group the intention-to-treat analysis (n = 208) 
revealed an increase in walking distance after 4 weeks of 75% (placebo, 43%). At the end of 
the interval treatment the walking distance had improved to 101% (placebo, 60%). The 
results remained virtually constant during follow-up (PGE1, 104%, placebo, 63%). Between- 
group comparisons showed significant differences in favor OfPGE 1 for all three time points 
of measurement (p < 0.05, p < 0.01, and p < 0.05). PGE l was well tolerated; the rate of 
adverse reactions related to the treatment was 12.8% (placebo, 7.7%). In summary, these 
results how that the new PGE 1 re u/men is effective and safe in the treatment of outpatients 
with intermittent claudication. (J Vase Surg 1997;25:537-44.) 
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Intermittent claudication (stage I I  according to 
Fontaine's classification) is a major manifestation of  
peripheral arterial disease. There is a general agree- 
ment that primary treatment should be conservative, 
comprising exercise training and the elimination of  
risk factors. 14 However, according to recent estima- 
tions merely 30% of  all patients with intermittent 
claudication benefit from physical training, s For pa- 
tients who do not respond to physical training and in 
whom the anatomic distribution of  the lesions is 
suitable for revascularization, angioplasty or surgery 
may be considered. Although the outcome ofpercu- 
taneous transluminal angioplasty has been shown to 
be excellent, with a 5-year patency rate of  up to 85% 
for stenoses of  iliac arteries, the results of  femoro- 
popliteal and crural percutaneous transluminal an- 
gioplasty remain poor. 1,6 In many of  these cases and 
in situations with an unfavorable b nefit-to-risk ratio 
for invasive measures, an improvement in walking 
distance can still be achieved by pharmacotherapy 
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Table I. Clinical studies with i.v. PGEl-treatment versus control in patients with severe intermittent 
claudication [pain-free walking distance < 200 m on treadmill (3 km/h,  12%)] 
Symptom-free Follow-up 
walking 
PGE 1 dosage Duration distance after Signif. vs. Sign. vs 
Study Control n (i.v.) (days) PGE~ control Months control 
Rudofsky 12 Placebo 50 outpatients 1 × 60 I~g 28 + 73% p < 0.01 - -  - -  
Diehm 9 Naffidrofuryl 48 inpatients 1 × 60 p~g 21 + 99% NS 3 p < 0.001 
1 × 600 mg i.v. 
Hepp l° Pentoxifylline 195 inpatients 2 x 40 ~g 28 + 119% p < 0.001 12 p < 0.05 
2 × 200 mg i.v. 
Scheffler 13 - Pentoxifylline 45 inpatients 2 × 40 ILg add. 28 + 263% p < 0.05 12 n.d. 
2 × 200 mg i.v. to training (excluding patients 
- Training with increases in 
walking distance 
> 1000 m) 
with prostaglandin E1 (PGE1). Recent studies dem- 
onstrate that the parenteral dministration of PGE 1 
(Alprostadil) markedly increases walking dis- 
tance. 7-13 In these trials intravenous PGE1 turned 
out to be superior to reference agents (pentoxifylline, 
naftidrofuryl), with an average improvement of ap- 
proximately 100% in hospitalized patients after a 
4-week treatment (Table I). Moreover, a signifi- 
cantly better long-term effect was observed with. 
PGE 1 up to 6 months after the end of therapy. 9,1°,13 
Up to now most of the patients reported in stud- 
ies with intravenous PGE 1 were treated under hospi- 
tal conditions. Therefore the question arises whether 
the same improvement can also be achieved in out- 
patients. From clinical observations and from studies 
we think that there might be a tendency for better 
results with the in-hospital treatment because of spe- 
cial care and more adequate control of concomitant 
diseases. For practical reasons it was at the same time 
interesting to examine whether even an "interval 
treatment" of only two intravenous PGE~ infusions 
per week would be able to increase the walking 
distance, because seeing the doctor daily can be dif- 
ficult, particularly for working patients. 
To answer all these questions a double-blind, 
placebo-controlled, multicenter t ial was conducted. 
With more than 200 patients involved, this study is 
one of the largest placebo-controlled trials in severe 
claudication of which we are aware. 
PATIENTS AND METHODS 
Ethical committee permission and signed in- 
formed consent of all patients was obtained accord- 
ing to local regulations governing research in human 
subjects. Eligible outpatients were male and female 
adults 45 to 75 years of age with severe intermittent 
claudication. No indication for revascularization pro- 
cedures was found in these patients. Diagnosis of 
arterial stenosis or occlusion of the above-knee or 
below-knee type was confirmed by angiography or 
digital subtraction angiography and ultrasono- 
graphic Doppler measurements of the systolic ankle- 
artery pressure. The patients had a history of claudi- 
cation of at least 6 months but no reduction in 
walking distance within the last 3 months before 
enrollment (stable stage II according to Fontaines's 
classification). Their maximum walking distance on 
the treadmill (walking speed 3 km/hr,  grade 12%) 
varied between 50 and 200 m at the time of enroll- 
ment. In nondiabetic patients ystolic ankle pressures 
at rest had to be at least 60 mm Hg ( to  avoid 
involving patients with possible critical limb isch- 
emia). 
Patients were excluded from the study if their 
maximum walking distance on the treadmill changed 
by more than 225% during the 2-week run-in-pc- 
riod. Furthermore patients were excluded for any of 
the following reasons: indication for revasculariza- 
tion procedures, primary aortoiliac disease, inflam- 
matory or immunologic vascular discases like Buer- 
ger's disease, congestive heart failure (New York 
Heart Association I I I / IV),  dccompensated renal 
failure (creatinine l vel >2 mg/100 ml), other vaso- 
active or rheologically active drugs, and supervised 
active physical training. 
The study was conducted at 16 medical centers 
adhering to the guidelines for therapeutic studies in 
peripheral arterial disease issued by the German Soci- 
ety ofAngiology 14 and to Good Clinical Practice and 
Food and Drug Administration guidelines. It was 
carried out as a multicenter, double-blind, placebo- 
controlled, randomized trial comparing two equally 
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Fig. 1. Study design (see text for details). 
3 weeks 
sized parallel groups of patients attending the anglo- 
logic outpatient clinic of the participating centers. 
The study design is illustrated in Fig. 1. In a 
2-week run-in phase painfree and maximum walking 
distances on the treadmill (walking speed 3 km/hr,  
12% grade) were assessed at the beginning, after 1 
week, and at the end. After run-in, eligible patients 
were randomized to receive ither PGE 1 or placebo. 
The treatment consisted of two phases of 4 weeks 
each. 
Phase I. During the first 4-weck treatment pe- 
riod patients rcceived intravenous infusions of 60 txg 
PGE 1 (corresponding to 3 ampoules of Prostavasin, 
Schwarz Pharma, Monhcim, Germany) or placebo 
dissolved in 100 ml normal saline solution and ad- 
ministered by constant infusion over a period of 2 
hours. Infusions were given once daily except on 
Saturdays, Sundays, and legal holidays. 
Phase II. In the second 4-week treatmcnt pe- 
riod ("interval therapy"), which immediately fol- 
lowed the first, the procedure and the composition of 
thc infusions remaincd unchanged, but their numbcr 
was reduced from five to two infusions per week with 
intervals of 2 to 4 days. To be eligible for evaluation 
in the per-protocol analysis patients had to rcceive at 
least 16 of the 20 infusions cheduled in the first and 
7 of the 8 infusions in the second treatment phase. 
On termination of the second treatment phase 
the trial medication was discontinued, and patients 
were monitored every 6 weeks for a period of 3 
months. 
At 11 visits during the 20-week study period the 
patients underwent clinical examinations (Fig. 1). 
On the first day a full history was taken, a physical 
examination was performed, an x-ray film of the 
chest was obtained, an elcctrocardiogram was re- 
corded, and heart rate and blood pressure were 
taken. Specific angiologic examinations included an- 
giography or Doppler ultrasonography and ankle sys- 
tolic pressure by Doppler ultrasonography. At the 
initial examination and at each of the following ones, 
painfree and maximum walking distances were deter- 
mined on the treadmill. Routine laboratory analyses 
were carried out on examinations 1, 5, 7, and 9. 
During the first 2 weeks of the first treatment period, 
blood pressure was taken immediately before and 
after the infusion. 
STATISTICAL ANALYSIS 
The primary variables for the evaluation of treat- 
ment efficacy were the relative changes in painfree 
walking distance from baseline. Calculation of the 
necessary sample size was based on the assumption of 
a reasonable effect size index of 0.4 for the logarithm 
of the relative change from baseline in painfree walk- 
ing distance between the two groups. To detect a 
difference of this magnitude with a power of 80% in a 
two-tailed ttest (~ = 5%), 101 patients per treatment 
group were required. 
Primary analysis compared the effect ofPGE 1 on 
painfree walking distance with that of placebo on an 
intention-to-treat basis including all randomized pa- 
tients. A secondary analysis involved only those pa- 
tients with no major protocol violations (per-proto- 
col analysis). 
For confirmatory evaluation of the primary vari- 
ables an analysis of variance (ANOVA) was per- 
formed for the symptom-free walking distance. As 
mentioned previously the dependent variable ana- 
lyzed was the logarithm of the change from baseline 
in symptom-free walking distance. This transforma- 
tion was used to limit the undue influence of possible 
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Table II. Selected characteristics before 
treatment of 208 outpatients with 
intermittent claudication i cluded in 
intention-to-treat analysis 
PGE 1 Placebo 
Patient characteristics (n = 106) (n = 102) 
Number of patients 106 102 
Male 75 80 
Female 31 22 
Mean age (yr) 62.5 62.0 
Mean height (cm) 169.5 169.9 
Mean body weight (kg) 75.3 75.7 
Mean history of clandication (yr) 4.28 3.56 
Mean ankle pressure index 0.585 0.595 
Mean pain-free walking distance (m) 64.3 66.6 
Mean maximum walking distance (m) 98.8 99.8 
Occlusion type (number of patients) 
Above-knee 66 54 
Below-knee 5 5 
Multiple-level 35 43 
Risk factors (number of patients) 
Hypertension 43 56 
Hyperlipidemia 72 68 
Hyperuricemia 11 14 
Diabetes mellitus 26 25 
Obesity 40 31 
Smokers 51 36 
Ex-smokers 41 49 
Previous therapy (number of patients) 
Surgical therapy ' 31 31 
Physical therapy 8 6 
Drug therapy 68 68 
extreme values} 5 The retransformed (by exponential 
function) treatment effects obtained by ANOVA cor- 
responded to the geometric mean of the relative 
changes of the original values. 
For descriptive analysis of the primary variables a
log-transformation was also used. The original walk- 
ing distances were transformed to their natural loga- 
rithm, analyzed, and afterwards backtransformed 
(arithmetic means of the log-transformed values corre- 
spond to the geometric means at the original values). 
RESULTS 
Of the 213 patients randomized no data on walk- 
ing distances in the first and second treatment period 
were available for five patients, leaving 208 patients 
for the intention-to-treat evaluation. Table II shows 
that patient characteristics did not differ significantly 
between the two treatment groups. In the course of 
the two double-blind treatment periods, protocol 
violations occurred in 42 cases, reducing the number 
of patients included in the per-protocol analysis to 
166. Because the results of the per-protocol analysis 
did not differ significantly from those of the inten- 
tion-to-treat nalysis, only the latter will be presented 
here in greater detail. 
The clinical efficacy ofPGE 1 proved to be clearly 
superior to that of placebo. The intention-to-treat 
analysis (n = 208) showed significant and clinically 
relevant increases from baseline in the painfree and 
maximum walking distances for PGE 1 (Fig. 2, Table 
III). At the end of the first treatment period the 
painfree walking distance i'n the PGE 1 group had 
increased by 75.3% (placebo, 43.3%). At the end of 
the interval treatment the walking performance of 
the patients treated with PGE 1 had improved to 
101% above baseline (placebo, 60.1%). During fol- 
low-up walking capacity did not decline but re- 
mained virtually constant at the newly gained levels. 
At the final examination after 3 months the average 
increase in painfree walldng distance in the PGE 1 
group amounted to 104% (placebo, 63.3%). Be- 
tween-group comparisons showed significant differ- 
ences in favor of PGE1 for all three times of measure- 
ment (p < 0.05, p < 0.01, andp < 0.05). 
In the per-protocol analysis (n = 166) the results 
were similar. The painfree walking distance in the 
PGE 1 group had increased by 84% (placebo, 54%), at 
the end of the interval therapy by 137% (placebo, 
86%), and after a 3-month follow-up to 119% (place- 
bo, 75%). All between-group comparisons were sig- 
nificant in favor of PGE1 (p < 0.05, p < 0.01, p < 
0.05). 
Thc superiority of PGE1 over placebo is also 
evidcnt when the maximum walking distance is con- 
sidered (Table III). Again, between-group compari- 
sons showed significant differences in favor of PGE 1 
(p < 0.05, p < 0.01, and p < 0.05). Evaluation of 
the ultrasound Doppler measurements revealed no 
significant differences between the two treatment 
groups for any of the Doppler ultrasonography pa- 
rameters investigated. Likewise no significant differ- 
ences were seen in the systolic and diastolic blood 
pressure values or in laboratory parameters between 
the groups. 
An additional exploratory subgroup analysis was 
done for diabetic and nondiabetic patients. From the 
descriptive results it appeared that PGE~ might be 
more beneficial to nondiabetics. This ex post gener- 
ated hypothesis, however, cannot be maintained, be- 
cause the groups were not comparable in terms of the 
number of cases (75% nondiabetics and 25% diabet- 
ics). Apart from this the diabetics in the PGE 1 group 
were a more unfavorable collection of patients with 
respect to age, severity of disease, and number of risk 
factors than the diabetics in the placebo group. 
Moreover the results of the subgroup analysis are at 
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Fig. 2. Descriptive statistics for painfree walking distance: geometric mean and standard errors 
at end points, p Values come from ANOVA model and indicate statistically significant differ- 
ences for relative changes from baseline in walking distance between two treatment groups 
(intention-to-treat analysis, ee text for details). 
odds with other studies and our own clinical experi- 
ence with this indication. 
An additional descriptive analysis of centers 
showed that there was a treatment-by-center interac- 
tion. This phenomenon is not unexpected and, ow- 
ing to the heterogeneity of the patients with periph- 
eral arterial disease, has been observed in other 
studies, too. 
There were no serious drug-related adverse 
events in both treatment groups. Adverse events that 
were rated to be possibly, probably, or definitely 
related to the study medication were seen in 12.8% of 
the patients treated with PGE 1 and in 7.7% of those 
given placebo. After infusion of PGE 1 mainly local 
effects uch as skin reddening or pain at the infusion 
site occurred. Only two patients reported izziness 
and nausea. No episodes of hypotension were seen. 
D ISCUSSION 
Whenever possible, treatment of intermittent 
claudication should be conservative. Therapy is gen- 
erally composed of the elimination of risk factors, 
particularly smoking, physical exercises, and drug 
treatment. Data from several studies trongly suggest 
that physical training is associated with an improve- 
ment in painfree and maximum walking dis- 
tance. 3,16-24 The benefit obtainable by intensive 
physical training over a period of 6 months ranged 
from 50% to almost 200%. The most successful pro- 
grams appear to be those combining regular super- 
vised exercises with daily home activities.2S However, 
because of contraindications for concomitant dis- 
eases and poor compliance, only one third of all 
patients with intermittent claudication actually par- 
ticipate in physical training programsP Therefore as 
an alternative or additive line of treatment, pharma- 
cologic measures also appear to be indicated. 
In the past years the vasoactive drugs pentoxifyl- 
line, naftidrofuryl, and buflomedil have been widely 
used in the conservative treatment of intermittent 
claudication. These agents are predominantly given 
orally on a long-term basis, but their clinical effec- 
tiveness is often inferior to that of physical exercise. 2s 
Recently, especially the intravenous infusion ofPGE 1 
has acquired increasing clinical importance. The effi- 
cacy of PGE 1 in claudication has been convincingly 
shown in controlled clinical trials (Table I). Even in 
well-trained patients who had successfully completed 
a standardized physical training program, the subse- 
quent intravenous administration of PGE 1 resulted 
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Table II I . Increases in pain-flee and maximum walking distances on treadmill (3 kin/h, 12% grade) 
after intravenous treatment with PGE 1 or placebo in 208 outpatients with intermittent claudication 
Pain-free walking distance 
Maximum walking 
distance 
PGE 1 , Placebo PGE 1 Placebo 
Time of measurement Statistics (n = 106) (n = 102) (n = 106) (n = 102) 
End of run-in phase = baseline geometric mean [m] 64.3 66.6 98.8 99.8 
(week 0) exp. (STD) 1.6 1.6 1.5 1.4 
End of first treatment phase geometric mean [m] 112.7 95.5 163.0 141.9 
(week 4) exp. (STD) 1.8 2.0 1.8 1.7 
End of interval treatment phase geometric mean [m] 128.9 106.6 186.3 i60.5 
(week 8) exp. (STD) 2.0 2.1 2.0 1.9 
End of follow-up phase geometric mean [m] 131.1 108.8 184.3 i63.6 
(week 20) exp. (STD) 2.1 2.3 2.0 2.0 
Intent-to-treat nalysis of the retransformed logarithmic values. 
Values shown are the geometric means [m] and the standard eviations retransformed bythe exponential function (exp(STD)). Data were 
prepared as follows: (1) Last value carried forward for the ends of the two treatment phases; (2) "Worst-case" procedure for the end of the 
follow-up phase; (3) Logarithmic transformation f values (natural logarithms). 
in a further increase in walking distance by nearly 
100%. 9 In addition to that, a first randomized pilot 
study shows that a 4-week combined course of intra- 
venous PGE 1 and intensive physical exercise results 
in a dramatic increase in the painfree walking dis- 
tance. 13 Although the increase achieved by exercise 
alone was 119%, additional administration of PGE 1 
increased the walking distance by 263%. In contrast, 
the combination of pentoxifylline and exercise pro- 
duced no better effect (105%) than exercise alone. 
In the controlled study reported here the efficacy 
of PGE 1 in claudication has been proven versus pla- 
cebo for the first time in a large number of outpa- 
tients. With regard to the sample size (n = 208) our 
study is one of the largest placebo-controlled trials 
conducted so far in the indication "severe intermit- 
tent claudication." In comparison with previous 
studies of PGE i the increase in painfree walking 
distance after an ambulatory 4-week-treatment 
(75%) is very similar to the results obtained in a 
placebo-controlled study of Rudofsky 12 (73%) in 50 
outpatients hat used the same PGE 1 dose and dura- 
tion of treatment. The increase in painfree walking 
distance on the treadmill is even more remarkable 
considering the fact that the study involved only 
severely diseased outpatients with a mean painfree 
walking distance of 64.3 m at the time of randomiza- 
tion. Moreover the increases in walking distance 
achieved under demanding treadmill conditions are 
equivalent to twofold to threefold increases under 
the conditions of normal everyday life, when the 
patients walk at their usual pace. 26 
A comparison of the benefit reported in this study 
with physical training programs is difficult. The clin- 
ical trials cited previously used a variety of exercise 
programs that appreciably differed in intensity and 
duration of training, sample size, and initial walking 
distance. Taking only the duration of treatment into 
consideration, the increase in walking capacity after a 
2-month exercise program is nearly comparable with 
that seen in our study. For example, Ernst et al? 4 
reported an increase in painfree walking distance of 
103%. 
The large placebo effect of 43% observed at the 
end of the 4-week treatment and of 60% at the end of 
the interval treatment is not unlcnown from the liter- 
ature. 25 One might speculate this is at least in part 
associated with intense patient surveillance and close 
physician attention and counseling regarding 
changes in health behavior. 
Seeing their doctor daily for receiving the infu- 
sion can be difficult or at times even impossible par- 
ticularly for working patients. For this reason it was 
interesting to investigate he effectiveness of a 4-week 
"interval treatment" regimen subsequent to the ini- 
tial therapy with only two instead of five infusions a 
week. This study is the first to demonstrate hat such 
an interval treatment produces an additional signifi- 
cant and clinically relevant improvement in walking 
performance. The attained increase in walking dis- 
tance appears to be not merely a short-term effect, 
because ven 3 months after termination of treat- 
ment it had not decreased. This finding confirms 
observations from other studies, 9,~°,13 even if at 
present here is no clear explanation for this long- 
term effect. Information to date suggests that PGE 1 
therapy leads to improved perfusion to occluded 
legs, improved nutritive blood flow, and more nor- 
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malized microcirculation and muscle metabolism. 27
Improvements in skeletal muscle metabolism facili- 
tate the extraction of oxygen and substrate and thus 
allow for a greater walldng ability. Moreover one 
might speculate that apart from its well- lmown vaso- 
dilating, antithrombotic,  leukocyte, and endothelial 
stabilizing effects, PGE 1 also directly influences col- 
lateral vessels, resulting in an increase in the total 
collateral capacity as it was shown by angiography in
men. 28 
Tolerance of treatment was excellent in both 
groups. Predominant  side effects were local phenom- 
ena such as skin reddening and sensation of pain in 
the area of the infused vein. All side effects related to 
PGE 1 therapy were mild and fully reversible. These 
findings are in agreement with the results of  a recent 
safety analysis of the pooled data from all published 
PGE 1 studies. 29 
In summary, intravenous PGE 1 is effective and 
safe in the treatment of outpatients with intermittent 
claudication. Our  study has shown the combinat ion 
of initial and interval therapy with PGE 1 to be a 
promising and practice-orientated therapeutic strat- 
egy. The intravenous infusion of PGE 1 should be 
considered for patients with claudication with re- 
stricted or lacldng trainability, in cases of  missing or 
inadequate response to physical exercise, or when a 
rapid improvement in walldng performance is desired 
(e.g., for occupational reasons). Moreover, recent 
preliminary findings uggest that the intravenous ad- 
ministration of PGE 1 is also beneficial as an addit ion 
to physical training. 
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